SWOG 0709: Randomized Phase II Trial of Erlotinib vs. Erlotinib plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay

BACKGROUND: Advanced stage non-small cell lung cancer (NSCLC) patients with borderline performance status (PS2) are often excluded from clinical trials and platinum-based therapy. In light of the potential role for serum proteomics in predicting erlotinib benefit beyond that of EGFR mutational statu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Oncol
Egile Nagusiak: Lara, Primo N., Moon, James, Hesketh, Paul J., Redman, Mary W., Williamson, Stephen K., Akerley, Wallace L., Hirsch, Fred R., Mack, Philip C., Gandara, David R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775366/
https://ncbi.nlm.nih.gov/pubmed/26725184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2015.11.003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak